Published in BJU Int on March 12, 2012
Increased pancreatic cancer risk following radiotherapy for testicular cancer. Br J Cancer (2016) 1.38
Seminoma stage 1: Patterns of care in Europe. BJU Int (2013) 1.08
Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med (2014) 1.01
Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer (2013) 0.85
Testicular cancer: Underestimating radiotherapy toxicity for stage I seminoma. Nat Rev Urol (2012) 0.75
Reply: Seminoma stage 1: Patterns of care in Europe. BJU Int (2013) 0.75
Evolution in management of stage I seminoma: the case for patient preference and patient/clinician joint internet registration and follow-up study to quantify late events. BJU Int (2012) 0.75
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet (2005) 6.99
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 6.16
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol (2011) 3.32
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol (2011) 3.10
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer (2004) 3.04
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol (2002) 2.88
Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol (2002) 2.78
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst (2007) 2.65
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol (2008) 2.56
Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol (2008) 2.55
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol (2008) 2.25
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol (2013) 2.16
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
EAU guidelines on testicular cancer: 2011 update. Eur Urol (2011) 1.96
Early outcomes of active surveillance for localized prostate cancer. BJU Int (2005) 1.84
Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost (2010) 1.80
Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer (2002) 1.79
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J Clin Oncol (2012) 1.77
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70
The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging (2010) 1.62
The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood (2011) 1.61
Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol (2002) 1.61
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol (2011) 1.58
PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer (2006) 1.52
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol (2012) 1.50
Diethylstilbestrol in castration-resistant prostate cancer. BJU Int (2012) 1.49
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer (2011) 1.45
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol (2009) 1.40
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int (2007) 1.35
Guidelines on testicular cancer. Eur Urol (2005) 1.32
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol (2011) 1.30
The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res (2010) 1.28
EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer (2009) 1.28
Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med (2007) 1.14
Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res (2006) 1.06
Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes Cancer (2008) 1.05
Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. Genet Epidemiol (2010) 1.04
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer (2012) 1.04
Extragonadal germ cell tumors: relation to testicular neoplasia and management options. APMIS (2003) 1.04
A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist (2012) 1.03
Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res (2014) 1.02
Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer (2002) 1.02
Current vaccination strategies for prostate cancer. Eur Urol (2011) 1.01
Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med (2014) 1.01
Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am J Pathol (2009) 1.00
Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad Sci U S A (2013) 1.00
18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review. Oncologist (2011) 1.00
Predictors of histological disease progression in untreated, localized prostate cancer. J Urol (2007) 1.00
Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer (2005) 1.00
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica (2007) 1.00
Update on management of seminoma. Indian J Urol (2010) 0.99
Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer (2010) 0.97
Adaptive-predictive organ localization using cone-beam computed tomography for improved accuracy in external beam radiotherapy for bladder cancer. Int J Radiat Oncol Biol Phys (2010) 0.97
The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagul Fibrinolysis (2011) 0.97
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int (2008) 0.96
A genome-wide association study of men with symptoms of testicular dysgenesis syndrome and its network biology interpretation. J Med Genet (2011) 0.96
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost (2010) 0.93
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother (2011) 0.92
The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer. Eur J Cancer (2011) 0.90
Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older. Cancer (2013) 0.89
No AZF deletion in 160 patients with testicular germ cell neoplasia. Mol Hum Reprod (2003) 0.89
Analysis of the polymorphic CAG repeat length in the androgen receptor gene in patients with testicular germ cell cancer. Int J Cancer (2002) 0.89
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. Int J Radiat Oncol Biol Phys (2010) 0.88
CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol (2003) 0.87
Emerging novel therapies for advanced prostate cancer. Ther Adv Urol (2012) 0.87
Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer (2005) 0.87
Polymorphic variation in the androgen receptor gene: association with risk of testicular germ cell cancer and metastatic disease. Eur J Cancer (2010) 0.86
Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer. BJU Int (2006) 0.86
Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy. BJU Int (2006) 0.86
Clinical and biochemical correlates of successful semen collection for cryopreservation from 12-18-year-old patients: a single-center study of 86 adolescents. Hum Reprod (2010) 0.86
Prospective study of factors predicting adherence to medical advice in men with testicular cancer. J Clin Oncol (2009) 0.86
Deep-sequencing analysis reveals that the miR-199a2/214 cluster within DNM3os represents the vast majority of aberrantly expressed microRNAs in Sézary syndrome. J Invest Dermatol (2012) 0.85
Identification of new genetic risk factors for prostate cancer. Asian J Androl (2008) 0.85
Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol (2010) 0.85
Association of polymorphisms in genes encoding hormone receptors ESR1, ESR2 and LHCGR with the risk and clinical features of testicular germ cell cancer. Mol Cell Endocrinol (2012) 0.85
Primary Adult Renal Ewing's Sarcoma: A Rare Entity. Sarcoma (2009) 0.85